Pulmotect Inc.
Synthetic inhaled drug prevents pneumonia in cancer patients
This article was originally published in Start Up
Executive Summary
Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.
You may also be interested in...
Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Start-Up Spotlight: Tyto Care Brings Medical Exams To Homes
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
Need a specific report? 1000+ reports available
Buy Reports